References
- Mayer R J, Davis R B, Schiffer C A, Berg D T, Powell B L, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896–903
- Bishop J S, Matthews J P, Young G A, Bradstock K, Lowenthal R M. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leukemia & Lymphoma 1998; 28: 315–327
- Burnett A K, Goldstone A H, Stevens R M, Hann I M, Rees J K, Gray R G, Wheatley K. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial. Lancet 1998; 351: 700–708
- Alberts D S, Young L, Mason N, Salmon S E. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by peritoneal administration. Seminars in Oncology 1985; 12(suppl 4)S38–S42
- Feldman E J, Alberts D S, Arlin Z, Ahmed T, Mittelman A, Baskind P, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993; 11: 2002–2009
- Feldman E J, Seiter K, Traganos F, Darzynkiewicz Z, Goff H, Pozzuoli M, et al. Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia. Leukemia & Lymphoma 2000; 38: 309–315
- Feldman E J, Seiter K, Damon L, Linker C, Rugo H, Ries C, et al. A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia 1997; 11: 485–489
- Seiter K, Feldman E J, Halicka H D, Deptala A, Traganos F, Burke H B, et al. Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukemia. Br J Haemotol 2000; 108: 40–47
- Slovak M L, Kopecky K J, Cassileth P A, Harrington D H, Theil K S, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075–4083
- Kaplan E I, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457
- Seiter K, Feldman E J, Sreekantaiah C, Pozzuoli M, Weisberger J, Liu D, et al. Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia 2001; 15: 963–970
- Pedersen-Bjergaard J, Andersen M K, Christiansen D H, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002; 99: 1909–1912
- Schiffer C A, Dodge R, Larson R A. Long-term follow-up of cancer and leukemia group B studies in acute myeloid leukemia. Cancer 1997; 80: S2210–S2214
- Leith C P, Kopecky K J, Chen I M, Eijdems L, Slovak M L, McConnell T S, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 94: 1086–1099
- Leith C P, Kopecky K J, Godwin J, McConnell T, Slovak M L, Chen I M, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. a Southwest Oncology Group Study. Blood 1997; 89: 3323–3329
- Von Hoff D D, Layard M, Rozencweig M, Muggia F M. Time relationship between last dose of daunorubicin and congestive heart failure. Cancer Treatment Reports 1977; 61: 1411–1413
- Krishnan A, Bhatia S, Slovak M L, Arber D A, Niland J C, Nademanee A, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588–1593